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IgE-mediated food allergy is a potentially life-threatening allergic disease with an increase in prevalence in developed
countries over the past 15 years. Currently, there are no approved forms of therapy and the standard of care is dietary
restriction and ready access to emergency medications, such as self-injectable epinephrine and antihistamines.
Allergen-specific modalities of treatment currently being studied include oral immunotherapy (OIT) and sublingual
immunotherapy (SLIT). Both forms demonstrate the ability to desensitize patients to a variety of specific food
allergens and show great promise. However, more research is needed to evaluate the safety and efficacy of OIT
and SLIT prior to routine use in clinical practice.
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Food allergy is a major public health concern that affects
approximately 8% of US children [1]. The most common
food allergens that elicit IgE-mediated reactions include
milk, egg, peanut, tree nuts, wheat, soy, fish and shellfish
[2]. Of these, peanut allergy is the most common cause
of anaphylaxis in children presenting to the emergency
department, as well as the most common cause of fatal
food anaphylaxis [3,4]. The prevalence of peanut allergy
has tripled from 0.4% to 1.4% from 1997 to 2008 [5,6].
Approximately 85% of children allergic to foods such as
cow’s milk, egg, wheat and soy will outgrow their allergy,
whereas 80-85% of children allergic to peanut, tree nuts,
fish and shellfish will not [7].
There is currently no approved treatment or disease-
modifying therapy for the routine management of pa-
tients with food allergies. The present standard of care is
strict dietary avoidance of appropriately-diagnosed food
allergens and ready access to emergency medications,
such as self-injectable epinephrine and antihistamines
[2]. Despite parent and patient vigilance with food aller-
gen avoidance, accidental exposures resulting in clinical
symptoms do occur [8]. As a result, patients and their
families experience significant psychosocial burden and
diminished health-related quality of life [9,10]. Recent* Correspondence: wburks@email.unc.edu
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unless otherwise stated.efforts have focused on developing safe and effective
therapies for patients with food allergies, with the most
active research involving oral and sublingual immuno-
therapy (OIT and SLIT).Mechanism for the development of food allergy
Oral tolerance is the process by which previously
encountered proteins exposed to the gastrointestinal
tract are tolerated through the suppression of cellular
or humoral immune responses [11]. This suppression
occurs through a number of mechanisms including the
production of regulatory T cells (Tregs), the deletion of
antigen-specific T cells, or the induction of anergy in
antigen-specific T cells [11,12]. Food hypersensitivity is
thought to result from either the failure to establish or
the breakdown of existing oral tolerance [12]. Essen-
tially, food allergy starts with an initial sensitization
event to the food protein; however, the route and timing
by which sensitization occurs remains unclear. Patients
with a predisposition for food allergy develop a T helper
(Th)2-predominant immune response. Th2 cells secrete
cytokines including interleukin (IL)-4, IL-5 and IL-13,
which stimulate B cells to produce allergen-specific IgE.
These IgE antibodies bind to the surface of mast cells
and basophils by high affinity receptors and cross-link
upon re-exposure to the protein allergen, releasing me-
diators such as histamine, leukotrienes, cytokines andLtd. This is an Open Access article distributed under the terms of the Creative
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allergic reactions [13].
Allergen immunotherapy
Allergen immunotherapy is a form of treatment that
involves administering gradually increasing doses of
allergen over time to induce immunologic changes.
There are two possible immune states that can be achieved
through food allergen immunotherapy: desensitization
and tolerance. Desensitization occurs when daily allergen
exposure increases the threshold of clinical reactivity to
the food. Patients are therefore able to tolerate more food
protein during an oral food challenge while on treatment.
When dosing is stopped or interrupted, the protection is
lost or reduced. However, the ultimate goal of allergen im-
munotherapy is tolerance, which is the ability to ingest the
food without allergic symptoms after discontinuation of
the therapy. Immunologic changes during immunotherapy
show a shift away from a Th2 profile with decrease re-
activity of mast cells and basophils, increase Treg produc-
tion, increase food-specific IgG4 antibodies and eventual
decrease in food-specific IgE antibodies [7].
Current protocols in food immunotherapy involving
OIT and SLIT typically comprise of 3 phases: (1) an initial
modified dose escalation or modified rush desensitization
that takes place over 1-2 days with 6-8 doses of the aller-
gen given, (2) a build-up phase that consists of weekly to
biweekly dose escalations performed over 6-12 months
and (3) a maintenance phase with daily home dosing that
occurs over months to years. Oral food challenges (OFC)
are used to test clinical reactivity while on treatment
(desensitization) and while off therapy but still on diet
restriction (tolerance) [7,14]. The initial desensitization
and dose escalations, as well as OFCs, are performed in
a supervised clinical setting while maintenance dosing
is carried out at home.
OIT
OIT involves the daily administration of food allergen
(milligrams to grams) mixed with a food vehicle in grad-
ually increasing doses over months to years. OIT has been
studied in several uncontrolled clinical studies for more
than a decade involving mainly milk, egg and peanut
allergies. Recent trials have provided invaluable efficacy
and safety data as well as compelling evidence that OIT
frequently induces desensitization, and possibly even
tolerance, in patients with food allergies (Table 1).
In 2012, Burks et al. published the first multicenter,
randomized, double-blind, placebo-controlled trial of
egg OIT [15]. The study was designed to evaluate the
clinical effect of egg OIT on desensitization and “sustained
unresponsiveness,” the ability to consume 10 g of egg-
white powder after 22 months of OIT and subsequent
avoidance of egg for 4 to 6 weeks. Fifty-five children wereenrolled with 40 subjects receiving egg OIT and 15 place-
bos. Subjects underwent a 1-day dose escalation, and a
build-up phase to a goal maintenance dose of 2000 mg.
After 10 months, subjects underwent the first 5 g OFC
where 22 (55%) active subjects passed (desensitized) ver-
sus none in the placebo group. The study was unblinded
at this point and the active treatment group was continued
on maintenance OIT until a 22-month 10 g OFC, during
which 30 (75%) of the active group passed (desensitized)
compared to 0 (0%) of the placebo group. Active subjects
who passed the 22-month OFC were taken off OIT for
4 weeks and returned for another 10 g OFC to determine
sustained unresponsiveness (tolerance). Eleven (28%)
active subjects passed and continued to incorporate egg
into their diet without symptoms. Symptoms occurred
with 25% of the total doses taken by the actively treated
subjects compared to 3.9% of placebo doses. No serious
therapy-related adverse reactions were reported. Egg
white-specific IgG4 was higher for subjects who passed
OFCs at 10, 22 and 24 months than for those who did
not. Higher IgG4 levels at 10 months also suggested
ability to pass OFCs at all 3 time points. Egg white-
specific IgE and basophil activation levels were lower at
10 months for subjects who passed the 22-month OFC
compared to those who failed.
In 2011, Varshney et al. published the first randomized,
double-blind, placebo-controlled study to date, which
conclusively demonstrated that peanut OIT induces
desensitization and immune modulation [16]. Twenty-
eight children were enrolled. However, 3 subjects with-
drew early leaving 16 subjects in the active treatment
group and 9 in the placebo group. The study protocol
included 1-day initial escalation, 44-week build-up and
4-week maintenance phases (goal maintenance dose
4000 mg peanut protein) followed by a 5 g OFC at about
1 year. All 16 (100%) subjects receiving OIT passed the
5 g OFC compared to the median cumulative dose tol-
erated by the placebo group of 280 mg. The peanut OIT
was well tolerated with subjects experiencing symptoms
after only 1.2% of build-up doses. No active subjects re-
quired epinephrine with dose escalation visits or home
doses. Peanut OIT subjects showed decrease IL-5 and
IL-13, increase in peanut-specific IgG4 and peanut-
specific FoxP3 Tregs, but no significant change in
peanut-specific IgE at the time of OFC.
Subsequently, the first study to demonstrate clinical
tolerance, or sustain unresponsiveness, after peanut OIT
was recently published by Vickery et al. [17], who reported
end-of-study results from an initial pilot trial of peanut
OIT that was published in 2009 [18]. Twenty-four of 39
subjects originally enrolled in the pilot trial at 2 US cen-
ters were recruited to continue this OIT protocol. The
maximum daily maintenance dose was 4000 mg. Subjects
were treated for either a maximum duration of 5 years or
Table 1 Summary of selected studies reviewed










Tolerance n (%) Immunologic
changes
Safety data




clinical trial. Egg OIT
N = 55 5-11 yrs. No Dose = 2000 mg 30 (75%) passed 10 g
OFC and desensitized
at 22 mos. of OIT
8 11 (28%) at 23





No severe adverse events. 78%
of active OIT children had oral
or pharyngeal AEs vs. 20% in
placebo group
Duration = 22 mos.
Varshney et al., [16]
Randomized,
placebo-controlled
clinical trial. Peanut OIT
N = 28 1-16 yrs. No Dose = 4000 mg 16 (84%) passed
5 g OFC
3 Not assessed No change in IgE;
↑IgG4 and
peanut-specific FoxP3
Tregs; ↓IL-5 and IL-13;
↓skin prick tests
Initial escalation: 9 (47%) of 19 OIT
subjects had AEs with 2 requiring
epinephrine
Duration = 48 wks. Build-up doses: OIT subjects
experienced AEs with 1.2% of 407
doses, no epinephrine required




N = 39 1-16 yrs. No Initial pilot OIT trial:
Dose = 300 mg
Initial pilot OIT trial:
27 (93%) of 29












↓peanut, Ara h 1,
& Ara h 2 IgE, ↓peanut
IgE/total IgE ratio,
no change in peanut
IgG4 or functional activity
Initial pilot OIT trial: 92% with AE
during 1-day dose escalation;
46% of build-up doses
elicited symptomsDuration = 8 mos.
Continued OIT trial:
Dose = 4000 mg
Continued OIT trial:
24 (100%) of 24
passed 5 g
desensitization OFC
Continued OIT trial: No AEs
reported by treatment successes
with peanut exposure vs. 3 (14%)
of treatment failures reported mild
reactions
Duration = 5 yrs.




clinical trial. Peanut SLIT
N = 40 12-
37 yrs.
Yes Dose = 165-1386 mcg 14 (70%) in active
group vs. 3 (15%) in
placebo group were
responders
10 Not assessed No change in
peanut-specific IgE;
↑IgG4
First phase: AEs with 40.1% of 5825
peanut SLIT doses including 1
treated with epinephrine vs. 0.6%
of 6029 placebo doses
Dose for cross-over
group = 3696 mcg
Crossover High dose group:
33.3% of 5030 doses had AEs
Duration = 44 wks.









in all groups; ↓specific-
IgE and basophil re
sponse in combined OIT
Symptoms with 1802 (29%) of
6246 SLIT doses and 2402 (23%)




tract symptoms, more need for
B-agonist and antihistamines.
Epinephrine 2× in SLIT and 4× in OIT.
OITB dose =1000 mg 6 (60%) SLIT/OITB
OITA dose =2000 mg 8 (80%) SLIT/OITA
passed 8 g OFC
SLIT duration = 74 wks.
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than 2 kU/L or less than 15 kU/L with peanut skin prick
test response less than 5 mm and no peanut-related reac-
tions in the previous 6 months. Subjects then underwent
two 5 g DBPCFC. The first was a desensitization OFC
performed to assess clinical reactivity while receiving
treatment and the second was to evaluate for sustained
unresponsiveness after stopping OIT for 4 weeks. Twelve
(50%) of the 24 subjects consumed 5 g of peanut protein
and passed the open oral feeding of peanut butter with-
out symptoms. These subjects were considered to have
achieved sustained unresponsiveness and classified as
treatment successes. Immunologically, they had smaller
skin test results as well as lower peanut-specific IgE,
Ara h 1, Ara h 2 levels and peanut-specific IgE/total IgE
ratios. However, there were no between-group differences
in peanut IgG4 levels or Treg cell numbers. Although this
study lacked randomization and a placebo control group,
it describes for the first time that immune tolerance, or
sustained unresponsiveness, among children with peanut
allergy treated with OIT is possible.
SLIT
SLIT involves the administration of small drops of allergen
extract (micrograms to milligrams) under the tongue,
which is then eventually spit or swallowed. Doses are
approximately 1000-times less than OIT doses, but
SLIT protocols include similar escalation and mainten-
ance dosing [14,19]. The mechanism of action involves
allergen interaction with protolerogenic Langerhans
cells in the oral mucosa, resulting in suppression of the
allergic response [20]. SLIT has been shown to be
effective for other atopic diseases such as asthma and
allergic rhinoconjunctivitis [21,22]. A number of studies
involving SLIT and a variety of food allergens, including
kiwi [23], hazelnut [24,25], milk [26], peach [27] and
peanut allergies have been promising. Thus far, available
evidence suggests that SLIT is less effective than OIT
of inducing desensitization, but has a better safety
profile given the low dose of peanut allergen required
for treatment [28,29].
Fleischer et al. recently published results from a ran-
domized, double-blind, placebo-controlled multicenter
trial of peanut SLIT with a crossover design in which 40
subjects, adolescents and young adults, were enrolled
after baseline OFC of up to 2 g of peanut powder [30].
Subjects were randomized 1:1 across 5 sites to receive
either daily peanut or placebo SLIT. At 44 weeks, a 5 g
OFC was performed, followed by unblinding of the
protocol. Placebo-treated subjects were then crossed
over to receive higher dose peanut SLIT, followed by a
subsequent 5 g OFC after 44 weeks on SLIT. OFCs on
44 weeks of SLIT were compared to baseline OFCs from
both groups and subjects were considered responders ifthey successfully consumed 5 g or at least 10-fold more
peanut powder than at baseline. Fourteen (70%) active
subjects were considered responders compared to 3
(15%) placebo subjects. In peanut SLIT responders, the
median successfully consumed dose increased from 3.5
to 496 mg after 44 weeks on therapy. When challenged
again after 68 weeks of SLIT, the median dose consumed
again significantly increased to 996 mg. This study clearly
showed that peanut SLIT can safely induce a desensitized
state in a majority of subjects compared with placebo and
that the length of therapy can significantly affect the
amount of allergen consumed.
Combined SLIT/OIT
In the first study to compare SLIT with OIT, Keet et al.
published the results of a randomized clinical trial of
cow’s milk allergy in 30 children [29]. After entry
DBPCFC, all subjects were treated with SLIT for 4 weeks.
They were then randomized equally into 3 groups: (1)
continued SLIT escalation to 7 mg daily, (2) cross over
with OIT to 1000 mg (OITB), or (3) cross over with OIT
to 2000 mg (OITA). Subjects were challenged with 8 g
milk protein after 12 and 60 weeks of therapy. If they
passed the 60-week challenge, therapy was stopped and
challenges were repeated 1 and 6 weeks later to assess for
tolerance.
After therapy, 1 (10%) in the SLIT group, 6 (60%) in
the SLIT/OITB group and 8 (80%) in the SLIT/OITA
group passed the 8 g OFC. However, the food challenge
threshold increased in all subjects who completed the
full maintenance period: 40-fold for SLIT/SLIT, 159-fold
for SLIT/OITB and 54-fold for SLIT/OITA groups. After
1 week of avoidance, 2 subjects in the SLIT/OITB group
reacted during challenge. After 6 weeks off therapy, an
additional subject in the SLIT/OITB group and 3 subjects
in the SLIT/OITA group failed the OFC. Therefore, this
left 1 in the SLIT/SLIT and 8 in the combined SLIT/OIT
groups who were considered tolerant.
Adverse reactions occurred more frequently with SLIT
(29%) than OIT (23%) doses; however, while SLIT caused
more mild symptoms such as oral pruritus, OIT doses
caused more multisystem, gastrointestinal, upper and
lower respiratory tract symptoms, as well as increased
need for β-agonist and antihistamine treatment. Mechan-
istic studies revealed increased cow’s milk-specific IgG4 in
all groups, but decreased specific-IgE and basophil hista-
mine release only in the combined OIT subjects when
compared to baseline. The study showed that OIT was
more effective than SLIT alone in inducing desensitization
to cow's milk, but not without more systemic side effects.
While a handful of subjects achieved clinical tolerance
after 1 and 6 weeks of avoidance, it is still unclear how
long the clinical effects of immunotherapy lasts once ex-
posure is stopped.
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Recent studies, including those mentioned above, show
promising data for the use of immunotherapy in food al-
lergic patients. However, therapies such as OIT and SLIT
are not recommended for routine clinical practice and the
current standard of care in the treatment of food allergies
is allergen avoidance and ready access to self-injectable
epinephrine [31]. Despite these recommendations, a re-
cent article summarizes the results of a retrospective chart
review of patients treated with peanut OIT in 5 different
practices: 4 office-based practices in the United States and
1 hospital-based practice in Israel [32]. The authors report
a total of 352 treated patients who received 240,351 doses
of peanut, peanut butter, or peanut flour, and experienced
95 reactions that required epinephrine administration.
The study cites a success rate of 85% based on the number
of patients who achieved goal maintenance dose and a re-
action rate of 0.7 per 1000 doses during escalation and 0.2
of 1000 doses during maintenance. It should be noted that
the OIT methods used at each site were locally developed
and had considerable variability, including maintenance
doses ranging from 415 to 8000 mg, differences in selec-
tion criteria for enrolling patients, definition for mild
reactions and criteria for administering epinephrine.
Despite these differences, the authors conclude that
peanut OIT may be a suitable therapy when managed
by qualified allergists/immunologists.
However, several recent systematic reviews and meta-
analyses do not support this notion and conclude that
“there is insufficient evidence in terms of long-term
effectiveness, safety, and cost-effectiveness of peanut
OIT to recommend its routine use in clinical practice
[33,34].” At this time, variations in immunotherapy
protocols, such as study product used, starting and
ending doses, study schedule, blinding, use of placebo,
selection of study subjects and reporting of adverse reac-
tions, make direct comparisons and evaluation of true effi-
cacy and safety of OIT and SLIT difficult [35,36]. Experts
in the field strongly recommend that these experimental
therapies continue to be administered under the over-
sight of institutional review boards and the US Food
and Drug Administration as food OIT remains in a state
of equipoise [37].
Conclusions
Food allergy is an increasingly prevalent disorder in the
United States and other Westernized countries with no
definitive cure or approved treatment. Patients living
with food allergies are at risk of accidental ingestions
daily that can result in potentially life-threatening reac-
tions. Over the past decade, there has been resurgence in
interest and an increase number of clinical trials to evalu-
ate immunotherapy options for food allergy, particularly
OIT and SLIT. Several studies have demonstrated theability of OIT and SLIT to induce desensitization, in which
patients are able to tolerate the ingestion of more food
allergen while on treatment, and immunologic changes
with ongoing therapy. However, concerns and questions
still remain regarding the allergic side effects and the
development of immune tolerance with these therapies,
the ultimate goal of allergen immunotherapy in which
patients tolerate the ingestion of food off treatment.
Further research is needed to address the safety and ef-
ficacy of OIT and SLIT for long-term use.
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